ArticleCancer management and research2025
Characteristics and Outcomes of Soft Tissue Sarcoma in Saudi Arabia: A 10-Year Experience.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Soft tissue sarcomas (STS) are rare, heterogeneous malignancies representing less than 1% of solid cancers. Given the diversity of subtypes and the complexity of management, understanding regional epidemiological patterns is essential. This study aimed to evaluate the clinical characteristics, treatment strategies, and prognostic factors in STS patients in Saudi Arabia at a sarcoma center. Patients and Methods: This retrospective study included 214 patients with STS treated between 2010 and 2020. Patient demographics, tumor characteristics, clinical stage, and treatment modalities were collected using REDCap. Overall survival (OS) was estimated using Kaplan-Meier curves, and prognostic factors were analyzed using Cox regression. Statistical significance was set at p < 0.05. Results: The median age at diagnosis was 37 years (IQR: 25-49.5), and the median symptom duration before diagnosis was 8 months. Synovial sarcoma (20%) was the most common subtype, followed by liposarcoma (13.6%) and undifferentiated pleomorphic sarcoma (12%). Metastatic disease at diagnosis was reported in 39% of patients, with the lower limb being the most affected site (62.1%). Local treatment included surgery alone (45.3%), radiation alone (7.5%), and combined surgery and radiation (41.6%). Median OS was not reached in localized disease, whereas it was 26 months in metastatic cases (p< 0.01). Age ≥65 years (hazard ratio[HR]: 6.05, p=0.002), larger tumor size (HR: 9.12, p=0.04), and metastasis (HR: 8.77, p<0.001) were associated with worse survival. Tumors in extremities (HR: 0.38, p=0.04) and combined local therapy (HR: 0.13, p=0.009) were associated with better OS. Multimodal therapy improved OS in metastatic cases (p=0.004). Conclusion: STS in Saudi Arabia presents at a younger age, with prolonged symptom duration, and a high burden of metastatic disease. Despite these challenges, outcomes are comparable to global trends, particularly multimodal approaches. Future research should identify barriers to early diagnosis, improve healthcare access, and explore novel systemic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.